This randomized split-face clinical trial evaluates the combined use of intradermal botulinum toxin type A (BoNT-A) and hyaluronic acid biorevitalization (NCTF 135HA) for facial rejuvenation. Fifty-two participants received BoNT-A + HA on one side of the face and BoNT-A alone on the other. After 60 days, the combination showed significantly greater wrinkle reduction, skin hydration, firmness, radiance, and overall aesthetic improvement. Adverse effects were mild and transient, confirming the treatment’s strong efficacy, safety, and high patient satisfaction.